Breaking Finance News

Amicus Therapeutics (NASDAQ:FOLD) target dropped to $16.50, released a report earlier today by Chardan Capital

Amicus Therapeutics (NASDAQ:FOLD) had its stock price target reduced to $16.50 by Chardan Capital in a report released Wednesday September 13, 2017. The new price target implies a potential upside of 0.24% from the company's previous stock price.

On Thursday August 10, 2017, Chardan Capital reported about Amicus Therapeutics (NASDAQ:FOLD) raised the target price from $12.50 to $17.50 that suggested an upside of 0.39%.

Only yesterday Amicus Therapeutics (NASDAQ:FOLD) traded 2.00% higher at $13.28. Amicus Therapeutics’s 50-day average is $13.21 and its two hundred day average is $9.61. With the last stock price close up 40.97% relative to the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the same time. 6,963,442 shares of FOLD traded hands, up from an average trading volume of 3,673,900

Recent Performance Chart

Amicus Therapeutics (NASDAQ:FOLD)

With a total market value of $0, Amicus Therapeutics has with a 52 week low of $4.41 and a 52 week high of $14.37 .

Also covering Amicus Therapeutics's target, a total of 7 analysts have released a report on Amicus Therapeutics. The 12-month price target is $13.00 with two equity analysts rating the company a strong buy, three equity analysts rating the company a buy, 2 brokers rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 brokerages rating the company a sell.

General Company Details For Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.